Emeraid

What Emeraid does

Emeraid Inc. (株式会社Emeraid) is a privately held Tokyo-headquartered healthcare AI company founded in February 2024 as a University of Tokyo-originated R&D startup, operating from Sobunkan Building 3F, 6-25-14 Hongo, Bunkyo-ku. The company develops AI solutions that combine medical and life science research expertise with proprietary machine learning, serving medical institutions, pharmaceutical companies, academic research centers, and elderly care operators in Japan.

The technical offering is organized around three product lines built on the proprietary Healthcare AI Platform 'SUI' (翠): the SUI platform itself (data analysis and decision support foundation), the Solution Business delivering end-to-end AI-DX engagements spanning issue analysis, consulting, proof of concept, AI system development, and operational improvement, and Medical Data Analytics applying bioinformatics and chemoinformatics to electronic health records, laboratory results, vital signs, clinical research, and clinical trial data. Productized capabilities also include an AI-powered monitoring service that infers elderly residents' presence and abnormal behavior from electrical power consumption data without installing new devices (developed with BeMap), and a death time prediction model mockup application commissioned by Yokohama City University.

Emeraid operates a consultative enterprise sales motion in Japan, generating revenue through project-based AI-DX engagements and clinical data analytics services for partners including Integrity Healthcare (joint pharma clinical data analysis, Dec 2024 - Feb 2026), Yokohama City University, BeMap, CryptoAI, and the Japan Pharmaceutical Manufacturers Association. Customer contact is initiated via direct email inquiry to [email protected], pricing is quote-based and not publicly disclosed, and distribution relies entirely on direct engagement with no channel partners, self-serve product, or international footprint. The company is founder-led by CEO Rikuto Shima and CTO Jumpei Ukita, both with University of Tokyo research backgrounds, and is internally characterized as a small, lean team of researchers and engineers.

Name

Emeraid

Legal name

株式会社Emeraid

Website

https://emeraid.co.jp

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Emeraid Inc. is a Tokyo-based healthcare AI startup founded in 2024 that develops the proprietary SUI platform, AI-DX consulting, and medical data analytics, serving medical institutions, pharmaceutical firms, and academic research partners in Japan.

Ownership category

akta.pro rank

Product category

Healthcare AI Software

NAICS

Software Publishers (5132), Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industry

Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO)

Keywords

• Healthcare AI platform
• Medical data analytics
• AI-DX solutions
• Pharmaceutical AI services
• Elderly monitoring AI

Headquarters

HQ city

Hongo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Healthcare AI Platform Services: SaaS-based platform providing data analysis and decision support in healthcare using cutting-edge AI technology. Revenue generated from platform subscriptions and usage fees.
2. AI-DX Solution Projects: End-to-end consulting and development projects from issue analysis through system development and operational improvement. Revenue derived from project-based professional services engagements.
3. Medical Data Analytics Services: Clinical data analytics services for pharmaceutical companies and medical institutions including clinical research and trial data analysis.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Emeraid develops and sells a proprietary Healthcare AI Platform "SUI" (翠) that powers end-to-end AI-DX solution development and medical data analytics services for Japanese healthcare institutions, pharmaceutical companies, and universities. Its offerings include R&D implementation support, AI-driven management consulting, clinical and trial data analysis grounded in bioinformatics and chemoinformatics, and an AI-powered elderly monitoring service that analyzes household power consumption to detect emergencies without requiring new device installations.

Product overview

Emeraid operates as a healthcare AI research and development company offering a three-part product portfolio centered on its proprietary Healthcare AI Platform 'SUI'. The platform serves as the core technology foundation, which powers the Solution Business (providing end-to-end AI-DX consulting and implementation services from issue analysis through system development and operational improvement) and the Medical Data Analytics service (delivering bioinformatics and chemoinformatics-based analysis of clinical and trial data). The company positions itself as a University of Tokyo-born startup that fuses medical and life science research expertise with AI technology to create solutions that only Emeraid can deliver.

Differentiator

Problem solved

Functional benefit

Brands

• SUI (翠): Proprietary Healthcare AI Platform built on insights from in-house R&D projects and medical research. A technology foundation for data analysis and decision support in healthcare using cutting-edge AI technology.

Products and services

• Healthcare AI Platform 'SUI' (翠) Proprietary AI-powered data analysis and decision support platform for the healthcare industry, providing technology foundation for medical data analytics and AI-DX solution development. Targeted at Japanese healthcare institutions, pharmaceutical companies, and universities.
• Solution Business (AI-DX Solutions) End-to-end AI, software, and hardware consulting and implementation service covering issue analysis, proof of concept, AI system development, AI-driven management support, and new business development assistance for medical institutions and companies. Targeted at Japanese healthcare and pharmaceutical enterprises.
• Medical Data Analytics (Clinical / Trials) Biological and clinical data analytics service grounded in bioinformatics and chemoinformatics that integrates and analyzes electronic health records, laboratory results, vital signs, clinical research data, and clinical trial data. Supports clinical data analysis projects for pharmaceutical industry partners and healthcare institutions.
• AI Monitoring Service Using Power Data Machine learning-based monitoring service for elderly individuals and those living alone that detects presence and abnormal behavior in real time by analyzing existing power consumption data. Alerts pre-registered family members and emergency services in case of nighttime wandering or falls, without installing new devices or cameras. Marketed to Japanese care service operators and elderly monitoring service providers.

Quantifiable outcome

• Real-time emergency detection for elderly including nighttime wandering and falls

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Integrity Healthcare (株式会社インテグリティ・ヘルスケア)coreStrategic or Co-development Partner · 3 December 2024Collaborative project in the pharmaceutical industry. Emeraid and Integrity Healthcare jointly conducted clinical data analysis. Started December 2024, completed February 2026. Integrity Healthcare is a medical tech company developing YaDoc (disease management), YaDoc Quick (online consultation), and Smart One Health (PHR management) systems.
• Yokohama City University (横浜市立大学)coreStrategic or Co-development Partner · 1 August 2024Commissioned to develop mockup application for research project 'Construction of a Death Time Prediction Model through Patient Information Analysis'. Application used for research outcomes and future model improvements. Collaboration with Faculty of Medicine, Intensive Care Unit.
• BeMap (株式会社ビーマップ)coreTechnology or Integration · 23 April 2024Joint development of AI-powered monitoring service using power data. BeMap provides power consumption and occupancy data; Emeraid develops proprietary machine learning models. Service targets elderly and people living alone. BeMap is a software company founded in 1998 providing network technology services.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Preferred Networks: Japan-based deep learning company with healthcare and life science applications among its verticals. Comparable as a domestic AI R&D company exploring regulated, high-stakes domains including healthcare alongside broader industries.
• Z-Works: Japanese AI startup building elderly care and monitoring solutions, including nursing care record automation. Comparable as a Japanese AI company addressing the same elderly-care labor shortage and digitalization pain points.
• Tetsuyu Healthcare: Japanese healthcare technology company developing AI and remote-monitoring solutions for home medical and nursing care. Comparable in targeting Japan's aging-society needs with AI-driven care and monitoring offerings.

Direct peers

• LPIXEL: Japanese healthcare AI company specializing in medical image analysis and life science AI. Comparable as a Japan-based R&D-oriented AI startup serving pharma, research, and clinical customers with proprietary AI technology.
• MICIN: Japanese digital health company offering online medical consultation, clinical trial eConsent, and AI-enabled healthcare solutions. Direct peer in bringing AI and software to Japanese healthcare institutions and pharma for clinical and operational improvement.
• AI Medical Service: Japan-based medical AI startup developing AI-driven diagnostic support, initially focused on endoscopic image analysis. Closely comparable as a Japanese venture applying AI/ML to clinical decision support and pursuing regulated SaMD pathways.
• Medley: Japanese digital health platform operating across medical/nursing care job matching and telehealth. Comparable as a technology company modernizing healthcare operations and care delivery in Japan, addressing the same aging-society and labor-shortage pressures.
• Ubie: Japanese healthcare AI company providing AI-powered symptom checking and clinical decision support to medical institutions and consumers. Direct comparable in deploying AI to address healthcare workflow and patient triage challenges in the Japanese market.
• Integrity Healthcare: Japanese medical technology company providing disease management, online consultation, and PHR platforms. Both partner and competitor of Emeraid in AI-driven clinical data analysis for pharma and medical institutions in Japan.

Broad incumbents

• M3, Inc. Large Japanese healthcare platform serving physicians, pharma, and consumers with a wide portfolio. CTO Ukita previously worked as an ML engineer at M3. Broad incumbent operating across the same Japanese healthcare AI and data landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emeraid